Vaginal Yeast Infection: Symptoms, Treatment & Red Flags

Vulvovaginal candidiasis (VVC) describes symptomatic inflammation of the vaginal mucosa and adjacent vulva when Candida species—most commonly Candida albicans—shift from commensal colonisation to invasive hyphal forms that trigger cytokine release, epithelial oedema, and intense afferent itch signalling. The process is usually focal to the lower genital tract in immunocompetent hosts, but it shares risk pathways with mucosal oral thrush when cell-mediated immunity or glycaemic control falters.

From a nursing triage perspective, VVC is less a “single bug” label than a syndrome that must be distinguished from other causes of vaginitis and cervicitis. Lifetime symptomatic episodes are extremely common among reproductive-aged women; a smaller subset develops recurrent or azole-refractory disease where species identification and susceptibility testing change management.

US sexually transmitted infection guidance stratifies VVC so bedside teams match drug duration and diagnostic intensity to host factors. Use the table as a communication scaffold when handing patients to medical staff or sexual-health physicians.

↔On a small screen, swipe or scroll sideways to see the full table.

Classic VVC combines vulvar genital itching, burning, dyspareunia, and external dysuria with a thick white adherent discharge described as “cottage cheese” or curd-like. Erythema, fissures, and labial oedema are common; cervical friability is not expected—if mucopurulent cervicitis is seen, redirect testing toward STI algorithms.

Severe VVC can produce extensive vulvar excoriation that limits walking or voiding; recurrent cases may show lichenification from chronic scratching. Document lesion pattern, prior antifungal courses, contraceptive type, antibiotic exposure, glycaemic control, and sexual history to inform microscopy and culture triage.

C. albicans dominates uncomplicated episodes. Candida glabrata and other non-albicans species appear more often with recurrent disease, prior azole exposure, or diabetes; they may lack pseudohyphae on microscopy, lowering wet-mount sensitivity.

• Antibiotic-induced dysbiosis (especially broad-spectrum agents) and local corticosteroid overuse.
• Oestrogen-rich states: pregnancy, high-dose combined oral contraception, oestrogen therapy—support glycogen-rich epithelium that favours yeast adherence.
• Hyperglycaemia and glycosuria; iron deficiency and skin barrier disease are additional associations in specialist literature.
• Intravaginal practices that disrupt lactobacilli (douching, “feminine hygiene” soaps) increase mixed infection risk.

Clinical assessment

Combine symptom clusters with speculum findings when scope of practice allows; otherwise coordinate urgent clinician review for first-episode severe pain, bleeding, or pregnancy.

Bedside microscopy

Saline and 10% potassium hydroxide (KOH) wet mounts improve yeast and pseudohypha detection; a negative mount in a symptomatic patient should trigger yeast culture before repeating empiric therapy.

pH and office tests

VVC typically keeps vaginal pH <4.5; elevated pH should prompt concurrent bacterial vaginosis evaluation. Vaginal swab NAAT panels can assist but must be interpreted in clinical context—positive yeast DNA without symptoms is not an indication to treat.

Laboratory investigations

Send culture when episodes recur, symptoms persist after two azole courses, non-albicans suspected, or the host is immunocompromised. Susceptibility testing becomes relevant when fluconazole fails despite adherence.

1. Triage symptoms — exclude fever, pelvic peritonism, pregnancy bleeding, and haemodynamic instability.
2. Match phenotype — curd discharge + acidic pH + budding yeast on KOH supports VVC; fishy thin discharge suggests BV overlap requiring different therapy.
3. Select therapy lane — uncomplicated nonpregnant: intravaginal azole or single oral dose; pregnant: 7-day topical azole only; complicated: prolong induction then consider maintenance.
4. Define follow-up — review at 7–14 days if symptoms persist; earlier if dysuria worsens (rule out urinary tract infection) or if vaginal bleeding develops.
5. Escalate — recurrent or culture-proven azole resistance → gynaecology/infectious diseases; systemic symptoms → emergency assessment.

↔On a small screen, swipe or scroll sideways to see the full table.

First-line (uncomplicated, nonpregnant)

Intravaginal imidazole creams or ovules (e.g., clotrimazole or miconazole regimens ranging from 1 to 14 days depending on concentration) or a single 150 mg oral fluconazole dose yield high symptom relief when microscopy aligns. Counsel that oil-based products may weaken latex condoms or diaphragms for the treatment window.

Complicated induction

Severe inflammation: extend topical azole to 7–14 days or give two oral fluconazole doses 72 hours apart per CDC complicated VVC guidance. Recurrent disease: after induction, weekly fluconazole for six months reduces relapse frequency but relapse remains common after cessation—document informed discussion.

Non-albicans or azole failure

Culture-directed therapy is essential; boric acid 600 mg vaginal capsules nightly for 14–21 days may be used for selected refractory non-albicans cases in specialist pathways—never in pregnancy, and store safely because acute ingestion is toxic.

Special populations

Pregnancy: use only topical azoles for 7 days; avoid oral fluconazole. Renal/hepatic impairment: topical routes minimise systemic exposure; involve pharmacy before oral azoles. Drug interactions: oral azoles inhibit CYP enzymes—coordinate with prescribers when patients take warfarin, certain statins, or antiarrhythmics.

Topical nystatin is not a first-line intravaginal choice for VVC but remains relevant for oral mucosal candidiasis—avoid automatic substitution without microbiology input.

• Record symptom onset, LMP, pregnancy status, all recent antibiotics, and prior antifungal courses with exact dates—helps distinguish inadequate therapy from new infection.
• Align nursing documentation with laboratory orders for culture before the next antifungal dose when recurrence is suspected.
• Provide written safety-netting: return for spreading erythema, fever, flank pain, or inability to tolerate oral intake.
• Discuss sexual activity: uncomplicated VVC is not classically sexually acquired; treat male partners only if symptomatic balanitis is present.
• Harm-reduction counselling: discourage intravaginal yoghurt, garlic, or essential oils—irritant dermatitis complicates assessment.

Local complications include fissure-related secondary infection, severe dysuria with dehydration, and post-inflammatory pigment change. Systemic candidiasis is not a routine extension of uncomplicated VVC but remains on the differential when fever or neutropenia coexists.

Clinician-facing prevention focuses on modifiable drivers: narrow antibiotic duration, optimise glycaemia in diabetes, pause unnecessary vaginal douching, and review immunosuppressive load where feasible. Prophylactic antifungals around every antibiotic course are not evidence-backed for average-risk women.

Uncomplicated VVC usually clears within days of appropriate therapy. Recurrent disease often relapses after maintenance stops; set realistic expectations and emphasise follow-up culture plans when symptoms return within two months.

Language-sensitive care matters: patients may feel shame about genital symptoms—private rooms, closed-door triage, and normalising questions about sexual violence risk improve disclosure. For adolescents, consider safeguarding pathways when recurrent symptomatic episodes coincide with relationship coercion or inability to access prescriptions.

• Vital signs and pain score at presentation; repeat if fever develops after therapy starts.
• Fluid intake and voiding pattern when dysuria is prominent.
• Skin integrity around labia majora/minora; note fissure depth.
• Medication timing chart for multi-dose fluconazole induction regimens.
• Contraception method and latex compatibility after intravaginal oil-based products.
• Adherence barriers: cost, shift work, literacy—offer pharmacy-led packaging aids.

• Fever ≥38 °C with pelvic pain or rigors.
• Syncope, tachycardia out of proportion to pain, or suspected sepsis.
• Heavy vaginal bleeding or clots—not typical of isolated VVC.
• Neutropenic patients with new mucosal pain plus systemic symptoms.

Nursing-priority lens (NCSBN Clinical Judgment Measurement Model): recognise cues → analyse cues → prioritise hypotheses → generate solutions → take safe action → evaluate outcomes. These NCLEX-style clinical judgment practice items mix priority sorting, select-all-that-apply, deterioration trends, multi-patient triage, ordered teaching steps, and matrix matching—mirroring Clinical Judgment Measurement Model layers around infection control, sexual health safety netting, and antifungal stewardship for vulvovaginal candidiasis.